Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Assets (2016 - 2025)

Zevra Therapeutics' Assets history spans 11 years, with the latest figure at $284.7 million for Q4 2025.

  • For Q4 2025, Assets rose 59.85% year-over-year to $284.7 million; the TTM value through Dec 2025 reached $284.7 million, up 59.85%, while the annual FY2025 figure was $284.7 million, 59.85% up from the prior year.
  • Assets reached $284.7 million in Q4 2025 per ZVRA's latest filing, up from $270.1 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $284.7 million in Q4 2025 to a low of -$426000.0 in Q2 2022.
  • Average Assets over 5 years is $146.0 million, with a median of $138.8 million recorded in 2021.
  • Peak YoY movement for Assets: tumbled 100.31% in 2022, then surged 24869.48% in 2023.
  • A 5-year view of Assets shows it stood at $132.9 million in 2021, then fell by 13.24% to $115.3 million in 2022, then skyrocketed by 49.41% to $172.3 million in 2023, then increased by 3.37% to $178.1 million in 2024, then soared by 59.85% to $284.7 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Assets are $284.7 million (Q4 2025), $270.1 million (Q3 2025), and $256.3 million (Q2 2025).